Pathstone Family Office’s Intellia Therapeutics NTLA Stock Holding History

Pathstone Family Office’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$204K	Buy	6,438 +1,086	+20%	+$42.1K	﹤0.01%	1511
2023 Q2	$220K	Sell	5,352 -181	-3%	-$7.34K	﹤0.01%	1102
2023 Q1	$206K	Sell	5,533 -6,095	-52%	-$239K	﹤0.01%	1079
2022 Q4	$3.52M	Sell	11,628 -84	-0.7%	-$3.99K	0.03%	350
2022 Q3	$654K	Buy	11,712 +5,752	+97%	+$357K	0.01%	948
2022 Q2	$308K	Buy	5,960 +2,209	+59%	+$112K	0.01%	783
2022 Q1	$273K	Sell	3,751 -18	-0.5%	-$1.52K	0.01%	785
2021 Q4	$445K	Sell	3,769 -31	-0.8%	-$3.88K	0.01%	597
2021 Q3	$509K	Buy	3,800 +17	+0.4%	+$2.57K	0.01%	505
2021 Q2	$613K	Sell	3,783 -1,322	-26%	-$103K	0.02%	403
2021 Q1	$410K	Buy	5,105 +3,291	+181%	+$221K	0.01%	391
2020 Q4	$99K	Hold	1,814	–	–	﹤0.01%	392
2020 Q3	$36K	Hold	1,814	–	–	﹤0.01%	400
2020 Q2	$38K	Hold	1,814	–	–	﹤0.01%	348
2020 Q1	$22K	Hold	1,814	–	–	﹤0.01%	409
2019 Q4	$266K	Hold	1,814	–	–	﹤0.01%	377
2019 Q3	$24K	Hold	1,814	–	–	﹤0.01%	373
2019 Q2	$30K	Hold	1,814	–	–	﹤0.01%	396
2019 Q1	$31K	Hold	1,814	–	–	﹤0.01%	370
2018 Q4	$25K	Hold	1,814	–	–	0.01%	248
2018 Q3	$52K	Buy	+1,814	New	+$52.8K	0.02%	101
2018 Q2	–	Sell	-1,814	Closed	-$38K	–	270
2018 Q1	$38K	Hold	1,814	–	–	0.02%	119
2017 Q4	$35K	Buy	+1,814	New	+$41.9K	0.02%	72
2017 Q3	–	Sell	-1,814	Closed	-$29K	–	288
2017 Q2	$29K	Hold	1,814	–	–	0.01%	252
2017 Q1	$26K	Buy	+1,814	New	+$24.3K	0.01%	220
2016 Q4	–	Sell	-1,814	Closed	-$31K	–	170
2016 Q3	$31K	Hold	1,814	–	–	0.03%	77
2016 Q2	$39K	Buy	+1,814	New	+$48.3K	0.04%	63

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Pathstone Family Office's NTLA Position: Q3 2023 in Review

Pathstone Family Office increased its Intellia Therapeutics (NTLA) stake by 20% in Q3 2023, buying an estimated $42.1K and bringing the position to 6,438 shares worth $204K. The position accounts for ﹤0.01% of the portfolio, ranked #1511.

Pathstone Family Office first reported a position in NTLA in Q2 2016 and has held it in 27 quarters since. The position peaked at $3.52M in Q4 2022. 284 funds tracked by Wall St. Rank hold NTLA as of Q3 2023.

Pathstone Family Office held 6,438 shares of Intellia Therapeutics worth $204K as of Q3 2023.
Pathstone Family Office bought 1,086 Intellia Therapeutics shares in Q3 2023, an estimated $42.1K.
Intellia Therapeutics made up ﹤0.01% of Pathstone Family Office's portfolio in Q3 2023, its #1511 holding.
Pathstone Family Office first reported a position in Intellia Therapeutics in Q2 2016 and has held it in 27 quarters since.
Pathstone Family Office's Intellia Therapeutics position peaked at $3.52M in Q4 2022.
284 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2023.

Based on Pathstone Family Office's 13F filing for Q3 2023, filed 8 Nov 2023.